Biotech Values

[jbog]

Bristol-Myers to buy MyoKardia for $13.1B, or $225/share in cash, WSJ reports

Bristol-Myers (BMY) will buy MyoKardia (MYOK) for $225 a share in cash, or $13.1B, The Wall Street Journal's Jared S. Hopkins reports.

MyoKardia's lead pipeline drug, code-named mavacamten, treats a chronic heart condition that can cause irregular heart rhythms in some patients and even death. Bristol plans to ask U.S. health regulators next year to approve the drug, Bristol CEO Giovanni Caforio says.

Read more at:
https://thefly.com/n.php?id=3169816